Sarcoma Drugs Strategic Industry Research Report 2023-2024 & 2030, Competitive Profiles of 42 Players Including Amgen, Bayer, Eisai, Eli Lilly, Johnson and Johnson, Novartis, Pfizer Inc.
03 déc. 2024 08h48 HE
|
Research and Markets
Dublin, Dec. 03, 2024 (GLOBE NEWSWIRE) -- The "Sarcoma Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Sarcoma Drugs was...
Immunology Collaboration and Licensing Agreements Trends Report 2024: Explore 862 Detailed Contract Documents via SEC Submissions - Access Deal Payment Terms and Trigger Clauses
14 oct. 2024 06h46 HE
|
Research and Markets
Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
Autoimmune Collaboration and Licensing Agreements Analysis Report 2024 with Directory of 905 Deals Signed Since 2016 - Upfront, Milestone, Royalties Data by Company A-Z, Therapy Focus and Technology
25 sept. 2024 09h10 HE
|
Research and Markets
Dublin, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The "Autoimmune Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors - Global Strategic Business Report 2024-2030, with Coverage of Akeso, Alphamab Oncology, BioAtla, BioNTech, Sino Biological and Xencor
04 sept. 2024 09h41 HE
|
Research and Markets
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors - Global Strategic Business Report" has been added to ResearchAndMarkets.com's...
Celiac Disease Drugs Market - Global First Line of Treatment, Second Line of Treatment, Steroids & Immunosuppressive Drugs, Therapeutic Vaccines, Vitamins & Dietary Supplements Forecast 2024-2030
28 août 2024 06h03 HE
|
Research and Markets
Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The "Global Celiac Disease Drugs Market by Drug (First Line of Treatment, Second Line of Treatment), Type (Steroids & Immunosuppressive Drugs,...
AstriVax enters clinical phase with its novel vaccine platform technology
24 juin 2024 01h00 HE
|
AstriVax
The first participants have been dosed in SAFYR, a Phase I clinical trial to test the safety and efficacy of two prophylactic vaccines developed with AstriVax technology. The study will also provide...
Immunology Collaboration and Licensing Agreements Analysis Report 2024 with Directory of Deals Signed Since 2016 - Company A-Z, Therapy Focus and Technology Type
16 mai 2024 10h45 HE
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...
Autoimmune Collaboration and Licensing Deals Report 2024: Provides Details of 882 Autoimmune Deals Dating Back to 2016 by Company, Headline Value, Therapeutic Area and Technology Type
24 avr. 2024 04h24 HE
|
Research and Markets
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Autoimmune Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Autoimmune Collaboration and...
Histone Deacetylase 6 Drug Pipeline Research Report 2024: Comprehensive Insights about 20+ Companies and 26+ Pipeline Drugs
12 avr. 2024 10h06 HE
|
Research and Markets
Dublin, April 12, 2024 (GLOBE NEWSWIRE) -- The "Histone Deacetylase 6 - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Global Anticancer Drug Market Estimated to Reach USD 172.52 Billion in 2023 with Continued Growth Projected Through 2029
03 avr. 2024 11h51 HE
|
Research and Markets
Dublin, April 03, 2024 (GLOBE NEWSWIRE) -- The "Anticancer Drug Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F" report has been added to ...